<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b8c6f558-9cbd-4389-a8d7-a8c698c49093"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TYRVAYA safely and effectively. See full prescribing information for TYRVAYA. <br/>     <br/>TYRVAYA<sup>®</sup> (varenicline solution) nasal spray<br/>Initial U.S. Approval: 2006<br/>
   </title>
   <effectiveTime value="20240212"/>
   <setId root="014c93dc-5737-479c-a9f0-aaadac1ac298"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080478750" root="1.3.6.1.4.1.519.1"/>
            <name>Oyster Point Pharma, Inc.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="a68d096b-50a0-4d71-927c-36fe3e63a2ab"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240212"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73521-030" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Tyrvaya</name>
                        <formCode code="C42989" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SPRAY"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>varenicline</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="0.03"/>
                              <denominator unit="mL" value="0.05"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="82269ASB48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VARENICLINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W6HS99O8ZO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VARENICLINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="KH7I04HPUU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="4.2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43174" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PUMP"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73521-030-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20211020"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="4.2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43174" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PUMP"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73521-030-90" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20211020"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213978" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211020"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38284" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NASAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="8c00e994-5728-4d4b-8e45-790063449372"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.</paragraph>
               </text>
               <effectiveTime value="20240212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_d241b66a-25bb-47c2-892f-0b673efefa23">
               <id root="50490c75-df1a-4372-a271-e2ee6ba8bfca"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20211016"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>One spray in each nostril twice daily (approximately 12 hours apart). (<linkHtml href="#_2_1_Dosing_Information">2.1</linkHtml>) <br/>
                           </item>
                           <item>
                              <caption>•</caption>Prime with seven (7) actuations before initial use.  Re-prime with 1 actuation if not used for more than five (5) days. (<linkHtml href="#_2_2_Priming_Instructions">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Dosing_Information">
                     <id root="25d80f8f-6fc1-47b5-a950-d1b97376027e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosing Information</title>
                     <text>
                        <paragraph>Spray TYRVAYA once in each nostril twice daily (approximately 12 hours apart). If a dose is missed, resume regular dosing at the next scheduled dose time.</paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Priming_Instructions">
                     <id root="67551ed5-44dd-4373-97bb-e022e505e3d8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Priming Instructions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Priming</content>:  Prime TYRVAYA before initial use by pumping seven (7) actuations into the air away from the face.  When TYRVAYA has not been used for more than 5 days, re-prime with 1 spray into the air. Do not shake.</paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="a7d3f6a8-b62b-49a2-b891-901df2c4f940"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Nasal spray delivering 0.03 mg of varenicline in each spray (0.05 mL).</paragraph>
               </text>
               <effectiveTime value="20211016"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Nasal spray delivering 0.03 mg of varenicline in each spray (0.05 mL). (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_e25b3caf-08e6-4a5e-ae8a-01291e2b91a3">
               <id root="4c56d0f0-367b-4c20-b447-742ed4f0b8ad"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20211016"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_6_ADVERSE_REACTIONS">
               <id root="2e371cab-591d-480d-ba18-1782220efc48"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20240212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation. (<linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Oyster Point Pharma at 1-877-EYE-0123 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_b51fa779-4d85-4c6c-881b-60b20bbb7209">
                     <id root="011f10c5-2da1-4e68-b4a4-f9e5ed93a96a"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In three clinical studies of dry eye disease conducted with varenicline solution nasal spray, 349 patients received at least 1 dose of TYRVAYA. The majority of patients had 31 days of treatment exposure, with a maximum exposure of 105 days. </paragraph>
                        <paragraph>The most common adverse reactions reported in 82% of TYRVAYA treated patients was sneezing. Other common adverse reactions that were reported in &gt;5% of patients include cough (16%), throat irritation (13%), and instillation-site (nose) irritation (8%).</paragraph>
                     </text>
                     <effectiveTime value="20240212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_fa641660-03db-48af-b12d-c48dcb80cd7c">
               <id root="31c8ca57-cdc8-4f55-8a07-969d169cfe20"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211016"/>
               <component>
                  <section ID="ID_71287099-35a0-4d55-91cc-9975956d9b81">
                     <id root="594b0d60-d7fb-4cc3-9df6-86daf958ef30"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on TYRVAYA use in pregnant women to inform any drug associated risks. In animal reproduction studies, varenicline did not produce malformations at clinically relevant doses.</paragraph>
                        <paragraph>All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Pregnant rats and rabbits received varenicline succinate during organogenesis at oral doses up to 15 and 30 mg/kg/day, respectively. While no fetal structural abnormalities occurred in either species, maternal toxicity, characterized by reduced body weight gain, and reduced fetal weights occurred in rabbits at the highest dose (4864 times the MRHD on a mg/m<sup>2</sup> basis).</paragraph>
                        <paragraph>In a pre- and postnatal development study, pregnant rats received up to 15 mg/kg/day of oral varenicline succinate from organogenesis through lactation. Maternal toxicity, characterized by a decrease in body weight gain, was observed at 15 mg/kg/day (1216 times the MRHD on a mg/m<sup>2</sup> basis). Decreased fertility and increased auditory startle response occurred in offspring at the highest maternal dose of 15 mg/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9dc83f6b-ce4a-44a0-b3b5-cf4317ca4985">
                     <id root="f42b0e7a-05a6-4b74-ac35-4b10177f5a63"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of varenicline in human milk, the effects on the breastfed infant, or the effects on milk production. In animal studies varenicline was present in milk of lactating rats. However, due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk. </paragraph>
                        <paragraph>The lack of clinical data during lactation precludes a clear determination of the risk of TYRVAYA to an infant during lactation; however, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TYRVAYA and any potential adverse effects on the breastfed child from TYRVAYA. </paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a9c30ced-2b3c-44ed-90d0-c684bd86d79d">
                     <id root="c54491fe-5566-49e7-aa89-34fb613ca8ef"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and efficacy of TYRVAYA in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d9d29675-7610-4800-9b1e-2a920f03dd9d">
                     <id root="b06d47d4-5a09-476d-8d29-11994f1855dc"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger adult patients. </paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_aa2d011a-d8b3-4820-a663-c15832c35f84">
               <id root="b237121a-5630-4f40-9e7a-f54b61d3451f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>TYRVAYA nasal spray contains varenicline which is a partial nicotinic acetylcholine receptor agonist of α4β2, α4α6β2, α3β4, and α3α5β4 receptors and a full α7 receptor agonist.</paragraph>
                  <paragraph>Varenicline, as the tartrate salt, is a powder which is a white to off-white to slightly yellow solid whose chemical name is 7,8,9,10-tetrahydro-6,10-methano-6<content styleCode="italics">H</content>-pyrazino[2,3-h][3]benzazepine, (2<content styleCode="italics">R</content>,3<content styleCode="italics">R</content>)-2,3-dihydroxybutanedioate (1:1). It is highly soluble in water. Varenicline tartrate has a molecular weight of 361.35 Daltons and a molecular formula of C<sub>13</sub>H<sub>13</sub>N<sub>3</sub> ⋅ C<sub>4</sub>H<sub>6</sub>O<sub>6</sub>. The chemical structure is:</paragraph>
                  <renderMultiMedia ID="id447" referencedObject="MM03000001"/>
                  <paragraph>TYRVAYA (varenicline solution) nasal spray is formulated for intranasal use as a clear 0.6 mg/mL strength solution, at pH 6.4.  After priming <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_2_2_Priming_Instructions">2.2</linkHtml>)]</content>, each actuation delivers a 0.05 mL spray containing 0.03 mg varenicline free base, equivalent to 0.05 mg of varenicline tartrate. The formulation also contains the following inactive ingredients: sodium phosphate dibasic heptahydrate, monobasic sodium phosphate anhydrous, sodium chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection.</paragraph>
               </text>
               <effectiveTime value="20211016"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>The chemical structure </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="varenicline-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_87e2eb94-b377-4cce-abae-7cdb2c6285c3">
               <id root="ab2cd2c6-78a9-4239-9192-03fa4a9a3c92"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211016"/>
               <component>
                  <section ID="ID_46ece58d-5526-4f98-abbe-9cabb3aa4c91">
                     <id root="c0b5a0f5-0120-4789-bb61-5bfd822451f5"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The efficacy of TYRVAYA in dry eye disease is believed to be the result of varenicline's activity at heteromeric sub-type(s) of the nicotinic acetylcholine (nACh) receptor where its binding produces agonist activity and activates the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease.  Varenicline binds with high affinity and selectivity at human α4β2, α4α6β2, α3β4, α3α5β4 and α7 neuronal nicotinic acetylcholine receptors. The exact mechanism of action is unknown at this time.</paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_414e7c0b-cc35-400c-967c-66234914584a">
                     <id root="e98cc352-7d20-41fc-addd-c84a6188671c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption/Distribution</content> </paragraph>
                        <paragraph>Following administration of 0.12 mg (0.06 mg per 50-µL spray in each nostril), a strength of varenicline that is higher than the labeled concentration, varenicline can be detected in plasma by 5 minutes, generally achieves peak concentration within 2 hours, with a mean C<sub>max</sub> of 0.34 ng/mL, and has an AUC<sub>0-inf</sub> of 7.46 h*ng/mL.  The systemic exposure (AUC<sub>0-inf</sub>) following this intranasal dose was approximately 7.5% of the exposure observed following a 1 mg oral dose of varenicline.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism/Elimination</content>
                        </paragraph>
                        <paragraph>The mean ± SD elimination half-life of varenicline after intranasal administration is approximately 19 ± 10 hours. Varenicline undergoes minimal metabolism with 92% excreted as unchanged drug in the urine.</paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6fac36d4-e405-4ad5-8c40-9e7e99e14f6f">
               <id root="1100b4c3-d155-40e1-b6d5-aaf99162c9af"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20211016"/>
               <component>
                  <section ID="ID_83ff3bd0-0e6d-4c67-aff2-52190526b558">
                     <id root="5c352eae-6d1c-4292-8c63-5a9959cf9777"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Lifetime carcinogenicity studies were performed in CD-1 mice and Sprague-Dawley rats. There was no evidence of a carcinogenic effect in mice administered varenicline by oral gavage for 2 years at doses up to 20 mg/kg/day (810 times the maximum recommended human dose [MRHD], on a mg/m<sup>2</sup> basis). Rats were administered varenicline (1, 5, and 15 mg/kg/day) by oral gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of hibernoma (tumor of the brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 405 times the MRHD on a mg/m<sup>2</sup> basis) and maximum dose (2 tumors, 15 mg/kg/day, 1216 times the MRHD on a mg/m<sup>2</sup> basis). The clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in female rats. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay; mammalian CHO/HGPRT assay; and tests for cytogenetic aberrations <content styleCode="italics">in vivo</content> in rat bone marrow and <content styleCode="italics">in vitro</content> in human lymphocytes.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered varenicline succinate up to 15 mg/kg/day (1216 times the MRHD on a mg/m<sup>2</sup> basis). Maternal toxicity, characterized by a decrease in body weight gain, was observed at 15 mg/kg/day. A decrease in fertility was noted in the offspring of pregnant rats administered varenicline succinate at an oral dose of 15 mg/kg/day. The decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (243 times the MRHD, on a mg/m<sup>2</sup> basis).</paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d72d9376-494d-4795-a8b9-43f97f7c059a">
               <id root="0cebd4c5-8c9a-47df-bc19-79bab17329fd"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of TYRVAYA for the treatment of dry eye disease was supported by two randomized, multi-center, double-masked, vehicle-controlled studies (ONSET-1 and ONSET-2).  In the ONSET-1 study, 182 patients were randomized in a 1:1:1:1 ratio to receive one spray in each nostril twice daily of varenicline solution 0.006 mg (N=47), TYRVAYA 0.03 mg (N=48), varenicline solution 0.06 mg (N=44), or vehicle (N=43). In the ONSET-2 study, 758 patients were randomized in a 1:1:1 ratio to receive one spray in each nostril twice daily of TYRVAYA 0.03 mg (N=260), varenicline solution 0.06 mg (N=246), or vehicle (N=252).</paragraph>
                  <paragraph>The majority of patients were female (74%), the mean (standard deviation [SD]) age was 61 (12.5) years, the mean (SD) baseline anesthetized Schirmer’s score was 5.1 mm (2.9), and the mean (SD) baseline eye dryness score (EDS) was 59.3 (21.6). Use of artificial tears was allowed during the studies. Enrollment criteria included minimal signs [i.e., anesthetized Schirmer's test score (range, 0-10 mm) and corneal fluorescein staining (range, 2-14)] and was not limited by baseline EDS (range, 2-100). </paragraph>
                  <paragraph>
                     <content styleCode="underline">Efficacy</content>
                  </paragraph>
                  <paragraph>Tear film production was measured by anesthetized Schirmer’s score assessed using a Schirmer’s strip (0-35 mm). The average baseline Schirmer’s score was 5.0 mm in the ONSET-1 study and 5.1 mm in the ONSET-2 study. Of the patients treated with TYRVAYA, 52% achieved ≥10 mm increase in Schirmer’s score from baseline in the ONSET-1 study and 47% achieved ≥10 mm increase in Schirmer’s score from baseline in the ONSET-2 study, compared to 14% and 28% of vehicle-treated patients in the ONSET-1 study and the ONSET-2 study, respectively at Day 28 (see <linkHtml href="#_RefTable1">Table 1</linkHtml>).   Of the patients treated with TYRVAYA, the mean change in Schirmer’s score was 11.7 mm and 11.3 mm as compared to 3.2 mm and 6.3 mm in the vehicle treated patients in the ONSET-1 study and ONSET-2 study, respectively at Day 28. </paragraph>
                  <table ID="_RefTable1" width="100%">
                     <caption>Table 1: Percent of Patients Achieving ≥10 mm Improvement from Baseline in Schirmer’s Score in 28-day Studies in Patients with Dry Eye Disease</caption>
                     <col width="35%"/>
                     <col width="19%"/>
                     <col width="13%"/>
                     <col width="20%"/>
                     <col width="13%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ONSET-1</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ONSET-2</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">TYRVAYA</content>
                                 <br/>
                                 <content styleCode="bold">N=48</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                                 <br/>
                                 <content styleCode="bold">N=43</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">TYRVAYA</content>
                                 <br/>
                                 <content styleCode="bold">N=260</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                                 <br/>
                                 <content styleCode="bold">N=252</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>≥ 10-mm increase in tear production (% of eyes) at Day 28</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>52%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>14%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>47%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>28%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>Proportion Difference (95% CI)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>38% (21%, 56%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>20% (11%, 28%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>p-value versus control</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>&lt;0.01</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>&lt;0.01</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Cochran-Mantel-Haenszel (CMH) test controlling for study site, baseline Schirmer’s test score (STS), and baseline EDS.<br/>All randomized and treated patients were included in the analysis and missing data were imputed using last-available data.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20211016"/>
            </section>
         </component>
         <component>
            <section ID="ID_3aa4ba6b-c090-4b6e-b487-991d0ac61421">
               <id root="85b7a548-3220-4c4b-b959-ec00d18d0857"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20211016"/>
               <component>
                  <section ID="ID_10a8891d-d930-46ed-b02b-6bac7080271a">
                     <id root="911bdf01-aff5-4d20-be25-3956f1c1a527"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>TYRVAYA (varenicline solution) nasal spray is available in a carton containing two (2) nasal spray amber glass Type I bottles.  Each bottle consists of a white nasal pump and blue dust cover, delivering 0.03 mg varenicline per spray (0.05 mL).  Each bottle delivers one spray in each nostril twice daily for 15 days.  </paragraph>
                        <paragraph>Two nasal spray bottles in each carton, containing 60 sprays per bottle, equivalent to 30-days’ supply with one spray in each nostril twice daily (NDC 73521-030-02).</paragraph>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ec76e0da-0094-478a-a98b-0e50ee0c61ac">
                     <id root="96bafaa5-5038-4914-9dc8-e3bb6b9b8c80"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Store TYRVAYA nasal spray at 20°C to 25°C (68°F to 77°F). Do not freeze.<br/>
                           </item>
                           <item>
                              <caption>•</caption>Discard TYRVAYA nasal spray bottle 30 days after opening bottle.</item>
                        </list>
                     </text>
                     <effectiveTime value="20211016"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_88C71D77-17BA-48A0-AEBF-0F0F433F4789">
               <id root="bb3ff334-8f4f-4d31-81c5-28474e5f2b7e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#ID_321af1a8-1148-44e9-ae83-edf9de71733d">Patient Information</linkHtml> and <linkHtml href="#ID_93ababe7-58aa-4e8c-b618-6eed718b4cd2">Instructions for Use</linkHtml>).</item>
                     <item>
                        <caption>•</caption>Instruct patients that TYRVAYA works to increase tear production in the eye after being sprayed in the nose.</item>
                     <item>
                        <caption>•</caption>Instruct patients to prime the bottle before using it for the first time by pumping seven (7) sprays into the air away from the face and to re-prime it by pumping 1 spray into the air away from the face if the bottle has not been used in more than five (5) days.</item>
                     <item>
                        <caption>•</caption>Instruct patients to wipe the nasal applicator with a clean tissue after each use.</item>
                     <item>
                        <caption>•</caption>Instruct patients to not shake or freeze the bottle.</item>
                  </list>
                  <paragraph>Manufactured for: Oyster Point Pharma, Inc., a Viatris company, 202 Carnegie Center, Suite 106, Princeton, NJ 08540</paragraph>
                  <paragraph>Copyrights and Trademarks are property of their respective owners.</paragraph>
                  <paragraph>TYRVAYA<sup>®</sup> is a registered trademark of Oyster Point Pharma, Inc., a Viatris company.</paragraph>
                  <paragraph>TYRVAYA<sup>®</sup> and/or the use of TYRVAYA<sup>®</sup> in a method may be covered by one or more patents or patent applications, available at www.oysterpointrx.com/patent-notices.</paragraph>
                  <paragraph>©2023 Oyster Point Pharma, Inc., a Viatris Company. All Rights Reserved.</paragraph>
                  <paragraph>OYP:TYRVA:R1</paragraph>
               </text>
               <effectiveTime value="20240212"/>
            </section>
         </component>
         <component>
            <section ID="ID_321af1a8-1148-44e9-ae83-edf9de71733d">
               <id root="7e1b0fea-4932-47fc-b0e2-5a706217d4ed"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Package Insert </title>
               <text>
                  <table styleCode="Noautorules" width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">TYRVAYA<sup>®</sup>
                                 </content> (Teer-vye-ah)</paragraph>
                              <paragraph>(varenicline solution)</paragraph>
                              <paragraph>nasal spray, for intranasal use</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is TYRVAYA?</content>
                              </paragraph>
                              <paragraph>TYRVAYA is a prescription nasal spray used to treat the signs and symptoms of dry eye disease.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before you use TYRVAYA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if TYRVAYA will harm your unborn baby.</item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if TYRVAYA passes into your breast milk. You and your healthcare provider should decide if you will use TYRVAYA if you plan to breastfeed.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph> </paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I use TYRVAYA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>See the Instructions for Use at the end of this Patient Information leaflet for information about the right way to use TYRVAYA.</item>
                                 <item>
                                    <caption>•</caption>TYRVAYA increases tear production in the eye after being sprayed in the nose.</item>
                                 <item>
                                    <caption>•</caption>Use TYRVAYA exactly as your healthcare provider tells you to use it.</item>
                                 <item>
                                    <caption>•</caption>Do not shake the bottles.</item>
                                 <item>
                                    <caption>•</caption>Spray TYRVAYA 1 time in each nostril, 2 times daily (about 12 hours apart).</item>
                                 <item>
                                    <caption>•</caption>A 1-month supply of TYRVAYA consists of 2 nasal spray bottles. Finish 1 bottle before opening the second. TYRVAYA comes in glass bottles with a white nasal pump and blue dust cover.</item>
                                 <item>
                                    <caption>•</caption>If you miss a dose of TYRVAYA, skip that dose and take your next dose at your regular scheduled time. Do not take an extra dose to make up for a missed dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of TYRVAYA?</content>
                              </paragraph>
                              <paragraph>The most common side effects of TYRVAYA include sneezing, cough, and throat and nose irritation.</paragraph>
                              <paragraph>These are not the only possible side effects of TYRVAYA. Call your doctor for medical advice about side effects.</paragraph>
                              <paragraph>You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store TYRVAYA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store TYRVAYA at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>
                                    <caption>•</caption>Do not freeze.</item>
                                 <item>
                                    <caption>•</caption>Throw away (discard) TYRVAYA nasal spray bottle 30 days after first use.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep TYRVAYA and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of TYRVAYA.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TYRVAYA for a condition for which it was not prescribed. Do not give TYRVAYA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TYRVAYA that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in TYRVAYA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> varenicline tartrate</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> sodium phosphate dibasic heptahydrate, monobasic sodium phosphate anhydrous, sodium chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection. </paragraph>
                              <paragraph> </paragraph>
                              <paragraph>TYRVAYA<sup>®</sup> is a registered trademark of Oyster Point Pharma, Inc., a Viatris Company.</paragraph>
                              <paragraph>TYRVAYA<sup>®</sup> and/or the use of TYRVAYA<sup>®</sup> in a method may be covered by one or more patents or patent applications, available at www.oysterpointrx.com/patent-notices.</paragraph>
                              <paragraph>Manufactured for: Oyster Point Pharma, Inc., 202 Carnegie Center, Suite 106, Princeton, NJ 08540</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration</paragraph>
                  <paragraph>Revised: 2/2024</paragraph>
                  <paragraph>OYP:PL:TYRVA:R1</paragraph>
               </text>
               <effectiveTime value="20240212"/>
            </section>
         </component>
         <component>
            <section ID="ID_93ababe7-58aa-4e8c-b618-6eed718b4cd2">
               <id root="91f16c8f-1709-4d13-b127-c6f328778ccd"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use  </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">TYRVAYA<sup>®</sup> </content>(Teer-vye-ah)<br/>
                     <content styleCode="bold">(varenicline solution)<br/>nasal spray, for intranasal use</content>
                  </paragraph>
                  <paragraph>Read this Instructions for Use before you start using TYRVAYA and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</paragraph>
                  <table width="100%">
                     <col width="50%"/>
                     <col width="50%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Important information you need to know before using TYRVAYA:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Parts of your TYRVAYA nasal spray:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold"> </content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">TYRVAYA is for use in the nose.</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not shake the bottles.</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <caption>•</caption>The TYRVAYA carton contains enough medicine for 30 days. <list listType="unordered">
                                       <item>
                                          <caption>o</caption>Each carton has 2 glass nasal spray bottles.<br/>
                                       </item>
                                       <item>
                                          <caption>o</caption>Each nasal spray bottle has enough medicine for 15 days of treatment.  <br/>
                                       </item>
                                       <item>
                                          <caption>o</caption>
                                          <content styleCode="bold">Do not </content>open the second nasal spray bottle until you have used the entire first bottle.<content styleCode="bold"> </content>
                                       </item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id-1190530298" referencedObject="ID_712cc097-5b81-403f-a1f1-62aff33b4d7f"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Steps for priming TYRVAYA before first Use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top"/>
                           <td valign="top"/>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 1.</content>  Remove the cap and the clip.  <br/>
                                 <br/>
                                 <content styleCode="bold">Do not</content> throw away the cap or the clip.  The cap and the clip will be placed back on to the nasal applicator after each use.</paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id2106912779" referencedObject="D219D2C8-EC84-4443-8B56-74D2DB63AD40"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 2. </content> Hold the nasal spray bottle upright and away from your face. Place 1 finger on each side of the base of the nasal applicator and place your thumb underneath the bottle.<br/>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id668984916" referencedObject="DDC7FB0B-94DD-4E8E-9A17-542160BF3113"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 3.</content>  Prime the nasal spray bottle by fully pressing and releasing the nasal applicator 7 times with your thumb and fingers. <content styleCode="bold">You may feel some resistance but be sure to press all the way down.</content> You may not see a spray released each time you press and release the nasal applicator. You should see a spray by the 7<sup>th</sup> time you press and release. Spray away from yourself and others.  <br/>TYRVAYA is now primed for use.</paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <br/>
                              <renderMultiMedia ID="id145642366" referencedObject="ID_4ebc4fb4-6dbc-4487-af02-463696c08064"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Reprime</content>:  If you do not use TYRVAYA for more than <content styleCode="bold">5 days</content>, you will need to reprime the nasal spray bottle with <content styleCode="bold">1 spray</content> before you start using it.  To reprime, hold the nasal spray bottle upright and away from your face and <content styleCode="bold">fully</content> press and release the nasal spray applicator <content styleCode="bold">1 time</content>.  <br/>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Avoid priming the nasal spray bottle more than needed</content>:  Priming the nasal spray bottle more than needed will reduce the amount of medicine in the nasal spray bottle. </item>
                  </list>
                  <table width="100%">
                     <col width="46%"/>
                     <col width="54%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode="Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Steps for using TYRVAYA nasal spray after priming</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top"/>
                           <td valign="top"/>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 1.  </content>Blow your nose to clear your nostrils, if needed.<content styleCode="bold"> </content>
                                 <br/>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id219419619" referencedObject="D67AAE89-3DFF-4F64-8EC1-16B1BDDDB1CE"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 2.</content>  Remove the cap and clip.  <br/>
                                 <br/>
                                 <content styleCode="bold">Do not</content> throw away the cap or the clip.  The cap and the clip will be placed back on to the nasal applicator after each use.<br/>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id1483728496" referencedObject="C9AD1766-B2B6-478C-B6B3-6D86C7CB772C"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 3.</content>  Hold the nasal spray bottle upright.  Place 1 finger on each side of the base of the nasal applicator and your thumb underneath the bottle.</paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id-1948615965" referencedObject="ID_86b73e93-7494-42bd-a7c7-6de1fc418756"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 4.  </content>Tilt your head back slightly without lying down.<br/>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id598378747" referencedObject="ID_291096a5-bbc9-4105-9333-c14db7ffd35e"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 5.</content>  Insert the nasal applicator into the left or right nostril.  Tilt the nasal applicator and point the tip of the nasal applicator towards the top of the ear on the same side as your nostril.  <br/>
                                 <content styleCode="bold">Do not</content> press the tip of the nasal applicator against the wall of the inside of your nose.  Leave a space between the tip of the nasal applicator and the wall of the inside of your nose.</paragraph>
                           </td>
                           <td valign="bottom">
                              <renderMultiMedia ID="id1806438604" referencedObject="CF953C67-88A9-4AA4-8A9E-858896F0FB65"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 6.  </content>Place your tongue to the roof of your mouth and breathe gently while <content styleCode="bold">fully</content> pressing and releasing the nasal applicator <content styleCode="bold">1-time</content> to release a spray into your nostril. <br/>Repeat Steps 5 and 6 to deliver a second spray in the other nostril. <br/>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id1103683865" referencedObject="BED998B5-0518-4CEC-9F04-95D853AA2A1C"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 7.</content>  Wipe the nasal applicator with a clean tissue.<br/>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <renderMultiMedia ID="id2063519008" referencedObject="ID_8ca3baa9-dc03-4bea-a018-6e53ef4486fe"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 8.</content>  Replace the clip and the cap.<br/>
                                 <br/>
                                 <br/>
                                 <br/>
                                 <content styleCode="bold">Repeat Steps 1 to 8 each time you use TYRVAYA.</content> </paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <renderMultiMedia ID="id1560897125" referencedObject="A7DA3094-3070-4C1B-AB73-E13D5A83DF29"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>TYRVAYA<sup>®</sup> is a registered trademark of Oyster Point Pharma, Inc., a Viatris company.</paragraph>
                  <paragraph>TYRVAYA<sup>®</sup> and/or the use of TYRVAYA<sup>®</sup> in a method may be covered by one or more patents or patent applications, available at www.oysterpointrx.com/patent-notices.</paragraph>
                  <paragraph>Manufactured for: Oyster Point Pharma, Inc., 202 Carnegie Center, Suite 106, Princeton, NJ 08540</paragraph>
                  <paragraph>©2023 Oyster Point Pharma, Inc.</paragraph>
                  <paragraph>Revised: 2/2024</paragraph>
                  <paragraph>OYP:IFU:TYRVA:R1</paragraph>
               </text>
               <effectiveTime value="20240212"/>
               <component>
                  <observationMedia ID="ID_712cc097-5b81-403f-a1f1-62aff33b4d7f">
                     <text>Tyrvaya Nasal Spray</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="D219D2C8-EC84-4443-8B56-74D2DB63AD40">
                     <text>Remove clip/cap</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DDC7FB0B-94DD-4E8E-9A17-542160BF3113">
                     <text>Step 2.  Hold the nasal spray upright and away from your face. Place one finger on each side of the base of the nasal applicator, and place your thumb underneath the bottle.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_4ebc4fb4-6dbc-4487-af02-463696c08064">
                     <text>Press 7 times/Fully Press</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="D67AAE89-3DFF-4F64-8EC1-16B1BDDDB1CE">
                     <text>Step 1.  Blow nose to clear nostrils if needed. </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C9AD1766-B2B6-478C-B6B3-6D86C7CB772C">
                     <text>Remove cap/clip</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_86b73e93-7494-42bd-a7c7-6de1fc418756">
                     <text>Step 3.  Hold the nasal spray upright.  Place one finger on each side of the base of the nasal applicator and your thumb underneath the bottle.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_291096a5-bbc9-4105-9333-c14db7ffd35e">
                     <text>Step 4.  Tilt your head back slightly.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="CF953C67-88A9-4AA4-8A9E-858896F0FB65">
                     <text>Step 5.  Insert the nasal applicator into the left or right nostril.  Tilt the nasal applicator and aim the tip towards the top of the ear on the same side.   DO NOT press the tip of nasal applicator against the wall of the inside of your nose.  Allow for a space between the tip of nasal applicator and the wall of the inside of your nose for proper dose administration. </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="BED998B5-0518-4CEC-9F04-95D853AA2A1C">
                     <text>Step 6.  Place tongue to the roof of the mouth and breathe gently while spraying 1 (one) time.  Repeat administration in the other nostril.  Wait 2 (two) or 3 (three) minutes before blowing nose if needed. </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_8ca3baa9-dc03-4bea-a018-6e53ef4486fe">
                     <text>Step 7.  Wipe the nasal applicator with a clean tissue.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="A7DA3094-3070-4C1B-AB73-E13D5A83DF29">
                     <text>Step 8.  Replace clip and cap.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a58b9148-f753-4cf4-8143-4c0a094666a7">
               <id root="93dc6f92-39bd-4688-a3ad-f3fd58fef935"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - NASAL SPRAY 0.03 mg </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 73521-030-02</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">tyrvaya<sup>®</sup>
                        <br/>(varenicline solution)<br/>nasal spray 0.03 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 nasal spray bottles<br/>for a 30-day supply</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each bottle contains 60 sprays<br/>(Net Content 4.2 mL per bottle)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRANASAL USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each 50 μL spray contains:</content>
                     <br/>varenicline 0.03 mg<br/>(equivalent to 0.05 mg<br/>varenicline tartrate)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content>
                     <br/>sodium phosphate dibasic<br/>heptahydrate, monobasic<br/>sodium phosphate<br/>anhydrous, sodium chloride,<br/>sodium hydroxide and/or<br/>hydrochloric acid (to adjust<br/>pH) and water for injection.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                     <br/>Oyster Point Pharma, Inc.<br/>Princeton, NJ 08540</paragraph>
                  <paragraph>1-877-EYE-0123</paragraph>
                  <paragraph>Store Tyrvaya between<br/>20°C to 25°C (68°F to 77°F).</paragraph>
                  <paragraph>Do not freeze.</paragraph>
                  <paragraph>Do not shake the bottles.</paragraph>
                  <paragraph>Discard individual bottle of<br/>Tyrvaya 30 days after first use.</paragraph>
                  <paragraph>Keep Tyrvaya and all<br/>medicines out of the reach<br/>of children.</paragraph>
                  <paragraph>02TRADCTN, Rev 2.0</paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">IMPORTANT</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Lrule " valign="middle">
                              <paragraph>Read enclosed <content styleCode="bold">Patient</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Information</content> and <content styleCode="bold">Instructions</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">for Use</content> for priming, dosing,</paragraph>
                              <paragraph>and re-priming information.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">PRIME BEFORE FIRST USE.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">FOR INTRANASAL USE.</content>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Tyrvaya, Oyster Point, and the respective logos<br/>are registered trademarks of Oyster Point Pharma, Inc.</paragraph>
                  <renderMultiMedia ID="id133452547" referencedObject="ID_55626b87-9224-4b6e-92f1-f610642b1bfb"/>
               </text>
               <effectiveTime value="20240212"/>
               <component>
                  <observationMedia ID="ID_55626b87-9224-4b6e-92f1-f610642b1bfb">
                     <text>0.03 mg Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>